FDA Alerts

After a clinical trial showed positive results in 89% of participants, a new drug regimen was approved by the FDA for highly drug-resistant forms of pulmonary tuberculosis.

The FDA issued a safety alert after results of a safety clinical trial showed increased risk of blood clots and death with higher dosages of the janus kinase inhibitor.

The FDA has approved Baqsimi nasal powder, the first glucagon therapy for the emergency treatment of severe hypoglycemia that can be administered without an injection.

A new 3-drug antibacterial drug injection containing an FDA-approved antibiotic and a new β-lactamase inhibitor has been approved.

The FDA has approved the first treatment option for chronic, inadequately controlled rhinosinusitis with nasal polyps.

The FDA has approved a new option for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women.

The FDA has approved a new injection for the treatment of pediatric patients 10 years or older with type 2 diabetes.

After a clinical trial showed the device was more effective than placebo, the FDA permitted marketing for the medical device that assists in the reduction of functional abdominal pain among adolescents with...

After a clinical trial showed the treatment was more effective than placebo, the FDA approved the first treatment for episodic cluster headache in adults that reduces the frequency of attacks.

The FDA has issued a warning to women of childbearing age against the use of dietary supplements that contain vinpocetine, due to risk for adverse effects on the fetus, including miscarriage.